Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Notice to Readers Revised Dosing Regimen for Malaria Prophylaxis with Mefloquine

A U.S. interagency group on malaria prevention has recently reviewed documented experience on the effectiveness and tolerance of mefloquine (Lariam((R))) for malaria prophylaxis. Based on this review, the group has proposed a change in the dosing regimen for malaria prophylaxis with mefloquine. Consequently, CDC has revised the dosing recommendations for mefloquine use. The new regimen consists of a single dose of mefloquine to be taken weekly, starting 1 week before travel. Prophylaxis should be continued weekly during travel in malarious areas and for 4 weeks after a person leaves such areas.

This notice updates the information in the following publications:

  1. CDC. Recommendations for the prevention of malaria among travelers. MMWR 1990;39(no. RR-3):4.

  2. CDC. Health information for international travel, 1990. Atlanta: US Department of Health and Human Services, Public Health Service, 1990:98; DHHS publication no. (CDC)90-8280. Detailed recommendations for the prevention of malaria may be obtained 24 hours a day by calling the CDC Malaria Hotline at (404) 332-4555.

Information about the availability of mefloquine can be obtained from the manufacturer at (800) 526-6367. Reported by: Malaria Br, Div of Parasitic Diseases, Center for Infectious Diseases, CDC.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.


All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #